Queen Elizabeth II Health Sciences Centre, Dalhousie University, 1278 University Avenue, Halifax, Nova Scotia, Canada.
Dermatology. 2010;221 Suppl 1:29-42. doi: 10.1159/000316179. Epub 2010 Aug 9.
Nail involvement in psoriasis is typically overlooked, although it can affect up to 50% of patients with psoriasis and cause functional impact as well as psychological stress that can significantly affect quality of life. In addition, psoriatic patients with nail disease tend to have a more severe skin condition, a higher rate of unremitting and progressive arthritis and more associated anxiety and depression. Historically, the treatment of nail psoriasis has proven difficult, with most patients feeling that the treatment for their nail disease was unsatisfactory. The current management of nail psoriasis includes topical, intralesional and systemic therapies, although little clinical evidence is available on the effectiveness of conventional treatments and, consequently, no specific treatment approach has been fully supported. Biologic agents are beginning to emerge as a viable option to treat patients with both cutaneous and nail clinical manifestations of psoriasis and psoriatic arthritis. The extra disease burden that nail symptoms place on the patient can be considered indicative of a more severe form of the disease and should be taken into consideration when assessing treatment options.
指甲受累在银屑病中通常被忽视，尽管它可能影响多达 50%的银屑病患者，并导致功能影响以及心理压力，从而显著影响生活质量。此外，患有指甲疾病的银屑病患者往往皮肤状况更严重，持续和进展性关节炎的发生率更高，且焦虑和抑郁更为相关。从历史上看，指甲银屑病的治疗已被证明具有挑战性，大多数患者认为他们的指甲疾病治疗效果不佳。指甲银屑病的目前管理包括局部、皮损内和全身治疗，尽管常规治疗的有效性的临床证据很少，因此，没有特定的治疗方法得到充分支持。生物制剂开始成为治疗银屑病和银屑病关节炎的皮肤和指甲临床表现患者的可行选择。指甲症状给患者带来的额外疾病负担可以被认为是疾病更严重的一种表现，在评估治疗选择时应予以考虑。
